Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.

Leukemia research - 1 Apr 2008

Stagno Fabio, Stella Stefania, Berretta Salvatore, Massimino Michele, Antolino Agostino, Giustolisi Rosario, Messina Angelo, Di Raimondo Francesco, Vigneri Paolo

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Blast Crisis
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Remission Induction

Share to Thiazoles

Source

Identifiers

PMID: 17889935
DOI: 10.1016/j.leukres.2007.08.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.PMID 17889935Read ↗

Imatinib resistance in chronic myeloid leukemia due to a rare mutation.Semantic proximity Read ↗

Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patientsSemantic proximity Read ↗

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.Semantic proximity Read ↗

Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?Semantic proximity Read ↗

Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient.Semantic proximity Read ↗

Resistance to targeted therapy in chronic myelogenous leukemia.Semantic proximity Read ↗

Resistance mutations in CML and how we approach them.Semantic proximity Read ↗

Resistance to imatinib: mutations and beyond.Semantic proximity Read ↗

Imatinib resistance in CMLSemantic proximity Read ↗

Haematological cancer: Ponatinib in CML - keeping PACE with multiple mutations.Semantic proximity Read ↗

Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.Semantic proximity Read ↗

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.